By physician referral or invitation only

AREN2231 (Unilateral Favorable Histology Wilms Tumor)

The purpose of this study is to improve the treatment of children and young adults with all stages of FHWT, so that more patients are cured without relapse, and that side effects from treatment are lessened without decreasing cure rates. This study will use information on higher or lower risk features of FHWT to adjust the treatment of each subject based on their risk of relapse.

Age & Gender

0 days ~ 29.9 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Thomas Alexander
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pediatric Cancers)

IRB Number

25-1003

ClinicalTrials.gov

NCT06401330

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.